Outlook Therapeutics, Inc. (OTLK) stock
OTLKNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends September 30
$0.36−0.04 (-8.94%)
Close on Nov 17, 2026Market cap $87.79MP/E –Yield –
Outlook Therapeutics operating margin
Operating margin is operating income as a percentage of revenue.
Outlook Therapeutics's operating margin for the twelve months ending Sep 30, 2019 was -445.6%. For fiscal 2025 it was -4744.3%, against -445.6% the year before. The highest annual figure on record is -445.6% in fiscal 2019.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | -4744.3% | −4298.7 |
| FY2019 | Sep 30, 2019 | -445.6% | +514.5 |
| FY2018 | Sep 30, 2018 | -960.1% | −18.8 |
| FY2017 | Sep 30, 2017 | -941.4% | +781.9 |
| FY2016 | Sep 30, 2016 | -1723.3% | −831.2 |
| FY2015 | Sep 30, 2015 | -892.1% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2025CQ2 2025 | Jun 30, 2025 | -1046.2% | −85.4 |
| Q4 FY2019CQ3 2019 | Sep 30, 2019 | -216.8% | +1391.4 |
| Q3 FY2019CQ2 2019 | Jun 30, 2019 | -966.7% | −31.4 |
| Q2 FY2019CQ1 2019 | Mar 31, 2019 | -1201.9% | −316.9 |
| Q1 FY2019CQ4 2018 | Dec 31, 2018 | -960.8% | −548.8 |
| Q4 FY2018CQ3 2018 | Sep 30, 2018 | -1608.2% | −1507.9 |
| Q3 FY2018CQ2 2018 | Jun 30, 2018 | -935.4% | +1484.8 |
| Q2 FY2018CQ1 2018 | Mar 31, 2018 | -885.0% | +1700.6 |
| Q1 FY2018CQ4 2017 | Dec 31, 2017 | -411.9% | +5458.4 |
| Q4 FY2017CQ3 2017 | Sep 30, 2017 | -100.3% | +1910.7 |
| Q3 FY2017CQ2 2017 | Jun 30, 2017 | -2420.1% | +2030.8 |
| Q2 FY2017CQ1 2017 | Mar 31, 2017 | -2585.6% | −2288.7 |
| Q1 FY2017CQ4 2016 | Dec 31, 2016 | -5870.3% | – |
| Q4 FY2016CQ3 2016 | Sep 30, 2016 | -2011.0% | – |
| Q3 FY2016CQ2 2016 | Jun 30, 2016 | -4451.0% | – |
| Q2 FY2016CQ1 2016 | Mar 31, 2016 | -296.9% | – |
See a number that looks wrong?